

November 15, 2019

Novartis Pharma AG
CH-4002, Basel, Switzerland

Reference: EudraCT 2012-005793-63/ Novartis Protocol ID CLIK066A2202

A multi-center, randomized, double-blind, double-dummy, parallel-group dose-finding study to evaluate the change in HbA1c after 12 weeks monotherapy with seven doses of LIK066 compared with placebo or sitagliptin in patients with type 2 diabetes

Trial CLIK066A2202 was cancelled with no patient enrollment and as such, no results will be reported.

Due to a flaw in the EudraCT system, the Global End of Trial date in the system only was changed to July 1, 2012 to allow upload of this letter to notify the public that this trial was cancelled and no patients were enrolled.